Literature DB >> 30735691

Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice.

D Matthew Walentiny1, Léa T Moisa2, Patrick M Beardsley3.   

Abstract

BACKGROUND: Fentanyl and its structurally related compounds have emerged as the most significant contributors to opioid overdose fatalities in recent years. While there is abundant information about the pharmacological effects of fentanyl, far less is known of its more recently abused analogs. The objective of this study was to determine whether fentanyl and several fentanyl-related substances would engender oxycodone-like responding in a mouse model of oxycodone discrimination. Oxycodone was selected as the training drug due to its high selectivity for mu opioid receptors. Compounds that elicited oxycodone-like responding in this procedure would likely evoke overlapping subjective experiences.
METHODS: Adult male C57BL/6 mice were trained to discriminate 1.3 mg/kg oxycodone from vehicle in a food-reinforced, two-lever choice procedure. Generalization tests were conducted with fentanyl and the following fentanyl-related compounds: ocfentanil, 3-furanyl fentanyl, crotonylfentanyl, and valerylfentanyl.
RESULTS: Fentanyl and each of its analogs completely generalized to the 1.3 mg/kg oxycodone discriminative stimulus and naltrexone pretreatment significantly decreased oxycodone-like responding for each compound. Rank order potency for engendering oxycodone-appropriate responding was ocfentanil > fentanyl > 3-furanyl fentanyl ≈ crotonylfentanyl > oxycodone > valerylfentanyl. Drug doses that evoked full substitution also significantly suppressed response rates compared to vehicle.
CONCLUSIONS: These results indicate that the discriminative stimulus, and by extension, the interoceptive and subjective effects of the tested fentanyl analogs, overlap with those of oxycodone. These observations consequentially support the prediction that they would also engender the likelihood for abuse similar to oxycodone. This article is part of the Special Issue entitled 'Opioid Neuropharmacology: Advances in treating pain and opioid addiction'.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug discrimination; Fentanyl; Fentanyl-related substance; New psychoactive substances; Opioid; Oxycodone

Mesh:

Substances:

Year:  2019        PMID: 30735691     DOI: 10.1016/j.neuropharm.2019.02.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Confronting the opioid crisis with basic research in neuropharmacology.

Authors:  Michael H Baumann; Gavril W Pasternak; Sidney S Negus
Journal:  Neuropharmacology       Date:  2020-01-17       Impact factor: 5.250

2.  Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances.

Authors:  Neil B Varshneya; D Matthew Walentiny; Lea T Moisa; Teneille D Walker; Luli R Akinfiresoye; Patrick M Beardsley
Journal:  Neuropharmacology       Date:  2019-03-20       Impact factor: 5.250

3.  Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.

Authors:  D Matthew Walentiny; Essie Komla; Léa T Moisa; Mohammed A Mustafa; Justin L Poklis; Hamid I Akbarali; Patrick M Beardsley
Journal:  Neuropharmacology       Date:  2020-12-11       Impact factor: 5.250

4.  Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors.

Authors:  Neil B Varshneya; D Matthew Walentiny; Lea T Moisa; Teneille D Walker; Luli R Akinfiresoye; Patrick M Beardsley
Journal:  Pharmacol Biochem Behav       Date:  2021-07-21       Impact factor: 3.697

Review 5.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

Review 6.  Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

Authors:  E Andrew Townsend; Matthew L Banks
Journal:  CNS Drugs       Date:  2020-05       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.